Ingrid Lund, Imaging Performance Partnership
As evidence regarding the effectiveness of CT lung cancer screening grows, many providers hope to implement CT lung cancer programs at their institutions. A few weeks ago, we spoke with Dr. Andrea McKee, director of the Rescue Lung, Rescue Life program at the Lahey Clinic.
She told us about building a top-notch lung cancer screening program at Lahey—and how to offer equal access to low-dose CT (LDCT) screening to patients at high risk for the development of lung cancer while decreasing overall costs for the system.
The case for lung cancer screening
Lindsay Conway, Oncology Roundtable
Although more and more cancer programs are offering low dose lung CT screening for high-risk patients, billing remains a challenge. Most payers still do not reimburse for the screening, and even when they do, there are often gray areas.
Below is a list of some of the questions I’ve received from members over the past year about billing for lung cancer screening. How are you managing these challenges? Please add your comments below, or email me at email@example.com.
Lung cancer screening billing and reimbursement challenges
Deirdre Fuller, Oncology Roundtable
After famously defeating the best “Jeopardy!” contestants two years ago, IBM’s supercomputer Watson is moving onto a more formidable challenge: Cancer.
IBM, the health insurer WellPoint, and Memorial Sloan-Kettering Cancer Center recently announced the release of two Watson-based apps that users can access through a tablet or computer. One application will assess treatments for lung cancer while the other will manage health insurance authorizations.
The doctor is in: Supercomputer Watson to be used in cancer care